maritide obesity drug news - Search News

Amgen says obesity drug caused up to 20% weight loss

What's Next for Amgen Obesity Drug After Investors Disappointed by Results

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

CNBC on MSN · 16h

Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau

The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.

BioPharma Dive · 11h

Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark

Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.

9h

Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

Benzinga.com20h

Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau

MariTide is expected to be delivered as a single dose in a handheld, autoinjector device with a monthly or less frequent ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results